GPT and Hepatic steatosis: The 150 mg group showed significant reductions in ALT (−30.4 U/L) and improvements in hepatic steatosis (−6.9%) as measured by MRI-PDFF, along with reductions in AST (−17.0 U/L) and body weight (−4.5 kg).